Active studies

Eligible infants: 28 weeks of gestation or less

This is a single center, masked randomized clinical trial funded by NHLBI (R34HL183268) in which extremely preterm infants fed human milk are randomly assigned to receive a DHA/ARA-enriched, fortified human milk diet administered during the first 14 days of life to reduce respiratory morbidity and improve lung function.

Eligible infants: 27 to 31 weeks of gestation and birthweight of 1500 grams or less

This is a multicenter, unmasked randomized clinical trial funded by NICHD (R01HD117932) in which very preterm infants fed human milk are randomly assigned to receive either 180 to 200 ml/kg/day or 140 to 160 ml/kg/day.

Eligible infants: 25 to 31 weeks of gestation

This is an unmasked, multicenter randomized clinical trial funded by The Gerber Foundation in which preterm infants fed human milk are randomly assigned to receive limited trophic feeding (20 to 25 mL/kg/day for one day) or extended trophic feeding (20 to 25 mL/kg/day for three days).

Eligible infants: 32 weeks of gestation or less, birthweight below the 25th percentile

This is a masked randomized clinical trial in which very preterm infants fed human milk are randomly assigned to receive a DHA/ARA supplement during the first 3 weeks after birth.

Eligible infants: 32 weeks of gestation or less

This is a prospective cohort study of human milk diets during the early postnatal development of premature babies. We want to establish the correlation between skeletal muscle mass (SMM) measured by the D3-creatine (D3Cr) dilution method and FFM measured by air-displacement plethysmography. The D3Cr method involves a one-time oral dose of D3Cr.

Eligible infants: 28 to 32 weeks of gestation

This prospective cohort study aims to assess whether preterm neonates born between 28-32 weeks of gestation retain excess water during periods of stagnant weight loss by measuring total body water at four time points using non-invasive bioelectrical impedance analysis (BIA).